tetano
Editor, Senior Moderator
J Med Virol
. 2022 Jan 20.
doi: 10.1002/jmv.27599. Online ahead of print.
Lymphadenopathy Post-COVID-19 Vaccination with Increased FDG Uptake May Be Falsely Attributed to Oncological Disorders: A Systematic Review
Khalifa Bshesh, Wafa Khan, Ahamed Lazim Vattoth, Emmad Janjua, Areej Nauman, Muna Almasri, Ateeque Mohamed Ali, Vinutha Ramadorai, Beshr Mushannen, Mai Al Subaie, Ibrahim Mohammed, Mais Hammoud, Pradipta Paul, Haya Alkaabi, Aliyaa Haji, Sa'ad Laws, Dalia Zakaria
Abstract
Coronavirus disease 2019 (COVID-19) has caused a global pandemic that continues to cause numerous deaths till to date. Four vaccines have been approved by the FDA as of July 2021 to prevent the transmission of COVID-19: Pfizer, Moderna, AstraZeneca, and Janssen. These vaccines have shown great efficacy and safety profile. One side effect that has been widely reported is post-COVID-19 vaccination lymphadenopathy. Due to the mimicry of the lymphadenopathy for metastases in some oncologic patients, there have been reports of patients who underwent biopsies which showed pathologic confirmation of benign reactive lymphadenopathy secondary to the COVID-19 vaccine. Therefore, understanding the incidence of lymphadenopathy post-COVID-19 vaccinations will help guide radiologists and oncologists in their management of patients, both present oncologic patients and patients with concerns over their newly presenting lymphadenopathy. A systematic literature search was performed using several databases to identify relevant studies that reported lymphadenopathy post-COVID-19 vaccination. Our results revealed that several cases have been detected in patients undergoing follow up FDG PET-CT scans where lymph nodes ipsilateral to the vaccine injection site show increased uptake of FDG. Thus, knowledge of the incidence of lymphadenopathy may help avoid unnecessary biopsies, interventions, and change in management for patients, especially oncologic patients who are at risk for malignancies. This article is protected by copyright. All rights reserved.
Keywords: AztraZeneca; COVID-19; COVID-19 Vacccine; Fluorodeoxyglucose (FDG) PET-CT scan.; Janssen; Lymphadenopathy; Moderna; Pfizer; coronavirus.
. 2022 Jan 20.
doi: 10.1002/jmv.27599. Online ahead of print.
Lymphadenopathy Post-COVID-19 Vaccination with Increased FDG Uptake May Be Falsely Attributed to Oncological Disorders: A Systematic Review
Khalifa Bshesh, Wafa Khan, Ahamed Lazim Vattoth, Emmad Janjua, Areej Nauman, Muna Almasri, Ateeque Mohamed Ali, Vinutha Ramadorai, Beshr Mushannen, Mai Al Subaie, Ibrahim Mohammed, Mais Hammoud, Pradipta Paul, Haya Alkaabi, Aliyaa Haji, Sa'ad Laws, Dalia Zakaria
- PMID: 35060149
- DOI: 10.1002/jmv.27599
Abstract
Coronavirus disease 2019 (COVID-19) has caused a global pandemic that continues to cause numerous deaths till to date. Four vaccines have been approved by the FDA as of July 2021 to prevent the transmission of COVID-19: Pfizer, Moderna, AstraZeneca, and Janssen. These vaccines have shown great efficacy and safety profile. One side effect that has been widely reported is post-COVID-19 vaccination lymphadenopathy. Due to the mimicry of the lymphadenopathy for metastases in some oncologic patients, there have been reports of patients who underwent biopsies which showed pathologic confirmation of benign reactive lymphadenopathy secondary to the COVID-19 vaccine. Therefore, understanding the incidence of lymphadenopathy post-COVID-19 vaccinations will help guide radiologists and oncologists in their management of patients, both present oncologic patients and patients with concerns over their newly presenting lymphadenopathy. A systematic literature search was performed using several databases to identify relevant studies that reported lymphadenopathy post-COVID-19 vaccination. Our results revealed that several cases have been detected in patients undergoing follow up FDG PET-CT scans where lymph nodes ipsilateral to the vaccine injection site show increased uptake of FDG. Thus, knowledge of the incidence of lymphadenopathy may help avoid unnecessary biopsies, interventions, and change in management for patients, especially oncologic patients who are at risk for malignancies. This article is protected by copyright. All rights reserved.
Keywords: AztraZeneca; COVID-19; COVID-19 Vacccine; Fluorodeoxyglucose (FDG) PET-CT scan.; Janssen; Lymphadenopathy; Moderna; Pfizer; coronavirus.